Cladribine Tablets: latest safety analysis
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
Giovannoni G, Berger J, Leist T et al.
Presented at the ACTRIMS-ECTRIMS MSVirtual Congress, September 11–13, 2020
• Update to the integrated analysis from the Cladribine Tablets clinical trial program (data cut-off October 2018)
• Contains information on the rate of serious treatment-emergent adverse events, infections, lymphopenia and malignancies, as well as respiratory viral infections
• Also contains post-approval safety data from the first patients to receive commercial Cladribine Tablets, cumulative to July 2020 – including information on cases of COVID-19
Updated safety of Cladribine Tablets in the treatment of patients with multiple sclerosis: integrated safety analysis and post-approval data
Cook S, Giovannoni G, Leist T et al.
Presented at the Consortium of Multiple Sclerosis Centers (CMSC) Virtual Poster/Platform Session, August 3, 2020
• Update to the integrated analysis from the Cladribine Tablets clinical trial program (data cut-off October 2018)
• Contains information on the rate of serious treatment-emergent adverse events, infections, lymphopenia and malignancies
• Also contains post-approval safety data from the first patients to receive commercial Cladribine Tablets, cumulative to January 2020 – including information on cases of COVID-19